>
How A Handful Of Billionaires Created The Transgender "Movement"
All Teslas in the US get a one month trial of FSD starting this week
Bill Banning Chemtrails Passes Tennessee Senate
Scientists Close To Controlling All Genetic Material On Earth
Doodle to reality: World's 1st nuclear fusion-powered electric propulsion drive
Phase-change concrete melts snow and ice without salt or shovels
You Won't Want To Miss THIS During The Total Solar Eclipse (3D Eclipse Timeline And Viewing Tips
China Room Temperature Superconductor Researcher Had Experiments to Refute Critics
5 video games we wanna smell, now that it's kinda possible with GameScent
Unpowered cargo gliders on tow ropes promise 65% cheaper air freight
Wyoming A Finalist For Factory To Build Portable Micro-Nuclear Plants
High-Speed Railway Progresses Towards 200-mph Dallas-Houston Line
27 Ft-tall 3D-printed Structure Built by New Robot | ICON's Multi-Story Robotic Construction Sys
Now researchers at MIT have identified a surprising new dynamic drug duo, combining two classes that are already beginning to be widely used. Interestingly, the combo appears to work in a completely different way to what scientists previously expected.
The researchers started with a class of drugs called PLK1 inhibitors, which have proven effective in the past and are beginning to be tested in phase 2 clinical trials. The team set out to boost the effects of this type of drug, to see if it could be made even more effective.
PLK1 inhibitors primarily work by messing with mitosis, the process cancer cells use to divide and spread quickly. But as a side effect, they can also cause oxidative damage to cells – and this is the area the team wanted to give a leg up to. The researchers reasoned that PLK1 inhibitors could be even more potent a cancer-killer if they paired them up with another drug that prevents cells from repairing oxidative damage.